Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tolebrutinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK known ✓ | Q06187 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | TEC | P42680 | 2/20 | 1.00 |
| ▸ | CD69 | Q07108 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.77 |
| ▸ | LCK | P06239 | 1/20 | 0.77 |
| ▸ | FYN | P06241 | 1/20 | 0.77 |
| ▸ | YES1 | P07947 | 1/20 | 0.77 |
| ▸ | LYN | P07948 | 1/20 | 0.77 |
| ▸ | HCK | P08631 | 1/20 | 0.77 |
| ▸ | SRC | P12931 | 1/20 | 0.77 |
| ▸ | CSK | P41240 | 1/20 | 0.77 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.77 |
| ▸ | BLK | P51451 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolebrutinib SCHEMBL18285624 | 1.00 | BTK (1.00) | BTKEGFRTECCD69RIPK2 | |
| Tolebrutinib SCHEMBL29999020 | 1.00 | BTK (1.00) | BTKEGFRTECCD69RIPK2 | |
| Tolebrutinib SCHEMBL18285621 | 1.00 | BTK (1.00) | BTKEGFRTECCD69RIPK2 | |
| SCHEMBL18644879 | 0.94 | BTK (0.89) | BTKEGFRTECCD69RIPK2 | |
| SCHEMBL18644867 | 0.93 | BTK (0.88) | BTKEGFRTECCD69RIPK2 | |
| SCHEMBL18644873 | 0.93 | BTK (0.88) | BTKEGFRTECCD69RIPK2 | |
| SCHEMBL18644866 | 0.93 | BTK (0.87) | BTKEGFRTECCD69RIPK2 | |
| SCHEMBL18644669 | 0.93 | BTK (0.86) | BTKEGFRTECCD69RIPK2 | |
| SCHEMBL18644876 | 0.93 | BTK (0.86) | BTKEGFRTECCD69RIPK2 | |
| SCHEMBL18644865 | 0.92 | BTK (0.85) | BTKEGFRTECCD69RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4531856-B1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK ABELLO AS (DK) | 2026-04-22 | — | — | EP | claimed |
| EP-4531856-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK-Abelló A/S (DK) | 2025-04-09 | — | — | EP | claimed |
| WO-2023232958-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | Alk-Abelló A/S (DK) | 2023-12-07 | — | — | WO | claimed |
| WO-2022081512-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF NEUROINFLAMMATORY DISEASES WITH BRUTON'S TYROSINE KINASE INHIBITORS | SYNUBI PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | WO | claimed |
| EP-4601647-A1 | THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MULTIPLE SCLEROSIS | Principia Biopharma Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| EP-4547249-A1 | THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MULTIPLE SCLEROSIS AND MYASTHENIA GRAVIS | Principia Biopharma Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4531856-A1 | BRUTON'S KINASE INHIBITORS FOR THE TREATMENT OF A SUDDEN ALLERGIC REACTION | ALK-Abelló A/S (DK) | 2025-04-09 | — | — | EP | disclosed |
| US-20250101021-A1 | METHODS OF MAKING TOLEBRUTINIB | PRINCIPIA BIOPHARMA INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4522170-A1 | BRUTON TYROSINE KINASE INHIBITORS FOR USE IN THE TREATMENT OF MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY DISEASE (MOGAD) | Principia Biopharma Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119421712-A | Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis | 普林斯匹亚生物制药公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119384411-A | Method for preparing tolmetinib | 普林斯匹亚生物制药公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-119212708-A | Therapeutic tyrosine kinase inhibitors for Myelin Oligodendrocyte Glycoprotein Antibody Diseases (MOGAD) | 普林斯匹亚生物制药公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4267572-A1 | 4-AMINO-3-(4-PHENOXYPHENYL)-1,3- DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE DERIVATIVES AND SALTS THEREOF | GENZYME CORPORATION (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116710452-A | 4-amino-3- (4-phenoxyphenyl) -1, 3-dihydro-2H-imidazo [4,5-C ] pyridin-2-one derivatives and salts thereof | 建新公司 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023122072-A1 | CRYSTALLINE FORMS OF (R)-1-(1-ACRYLOYLPIPERIDIN-3-YL)-4-AMINO-3-(4-PHENOXYPHENYL)-1H-IMIDAZO[4,5-C]PYRIDIN-2(3H)-ONE AND SALTS THEREOF | GENZYME CORPORATION (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-4093397-A1 | THERAPEUTIC TYROSINE KINASE INHIBITORS FOR RELAPSING MULTIPLE SCLEROSIS (RMS) | GENZYME CORPORATION (US) | 2022-11-30 | — | — | EP | disclosed |
| CN-115348862-A | Therapeutic tyrosine kinase inhibitors for Relapsing Multiple Sclerosis (RMS) | 建新公司 | 2022-11-15 | — | — | CN | disclosed |
| WO-2022212893-A1 | COMBINATION TREATMENT METHODS OF MULTIPLE SCLEROSIS | BIOGEN MA INC. (US) | 2022-10-06 | — | — | WO | disclosed |
| WO-2022140511-A1 | 4-AMINO-3-(4-PHENOXYPHENYL)-1,3- DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE DERIVATIVES AND SALTS THEREOF | GENZYME CORPORATION (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022081512-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF NEUROINFLAMMATORY DISEASES WITH BRUTON'S TYROSINE KINASE INHIBITORS | SYNUBI PHARMACEUTICALS LLC (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101021-A1 | METHODS OF MAKING TOLEBRUTINIB | ABL1, JAK2, JAK1 | BTK 37/4885EGFR 125/4885TEC 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.